Slide 1: Letter to stock exchanges: Investor/Analysts Presentation
AUROBINDO November 8,2021 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Sandra Kurla Complex, Sandra (E), Phiroz Jeejeebhoy Towers, MUMBAI -400 051 25th floor, Dalal Street, MUMBAI -400 001 Company Code No. AUROPHARM
Slide 2: Aurobindo Pharma Limited Earnings Presentation Q2FY22
Aurobindo Pharma Limited Earnings Presentation Q2FY22
Slide 3: Disclaimer
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma Limited, nor shall it, or any par
Slide 4: Index
Index Page Q2FY22 Business & Financial Highlights 4 Financial Performance 9 Filings Snapshot 12 Aurobindo Pharma Limited | Earnings Presentation – Q2FY22 3
Slide 5: Q2FY22 Business & Financial Highlights
Q2FY22 Business & Financial Highlights 4
Slide 6: Consistent Quarterly Performance (Excluding Natrol)
Consistent Quarterly Performance (Excluding Natrol) Revenue (Rs Crore) US Revenue ($ Mn) 6,069 6,065 6,007 5,942 5,540 5,702 390 401 374 393 364 361 Q1FY21 Q2FY21 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q1FY21 Q2FY21 Q3FY21 Q4FY21 Q1FY22 Q2FY22 EBITDA (Rs Crore) Net Debt to Equity* 1,295 0.08 0.08 1,281 1,276 1
Slide 7: Consolidated Financial & Business Highlights (Excluding Natrol) – Q2 FY22
Consolidated Financial & Business Highlights (Excluding Natrol) – Q2 FY22 Revenue from operations at Rs 5,941.9 crore, up 4.2% QoQ, US revenues at US$ 401.4 Million (up 10.3% QoQ) Research & Development (R&D) spend at Rs 399 crore, 6.7% of revenue (Q1 FY22: 6.3%) EBIDTA before Forex and Other income
Slide 8: US Business Performance Highlights (Excluding Natrol)
US Business Performance Highlights (Excluding Natrol) Revenue (Rs Crore) Revenue mix – Q2FY22 2,968 Orals 2,775 2,681 71.8% Total Injectables Injectables* 22.6% 16.9% Branded Oncology** Q2FY21 Q1FY22 Q2FY22 5.7% OTC 5.6% US Formulations • US revenue in Q2FY22 increased by 6.9% YoY to Rs. 2,967.6 cro
Slide 9: Europe, ARV, Growth Markets, API Business Revenues & Performance Highlights
Europe, ARV, Growth Markets, API Business Revenues & Performance Highlights In Rs Cr Europe Growth Markets ARV API 503 1,662 447 829 812 1,583 386 781 1,515 329 296 145 Q2FY21 Q1FY22 Q2FY22 Q2FY21 Q1FY22 Q2FY22 Q2FY21 Q1FY22 Q2FY22 Q2FY21 Q1FY22 Q2FY22 • Europe revenue in Q2FY22 increased • Revenue
Slide 10: Financial Performance
} | AUROBIND Committed to healthier life! 203 Windsor Center Drive
Slide 11: Consolidated Profit & Loss Statement (as reported)
Consolidated Profit & Loss Statement (as reported) Rs Cr Q2FY22 Q2FY21 (%) Chg Q1FY22 (%) Chg Revenue from operations 5,941.9 6,483.4 -8.4% 5,702.0 4.2% Gross Profit 3,436.3 3,967.7 -13.4% 3,335.8 3.0% Gross Margin 57.8% 61.2% -5.5% 58.5% -1.1% Overheads 2,249.6 2,534.9 -11.3% 2,126.4 5.8% EBITDA (b
Slide 12: Debt profile
Debt profile Debt as on (Rs Cr) Mar-18 Mar-19 Mar-20 Mar-21 Sep-21 Fx Loan US$ Mn Closing Rate1 US$ = 65.17 69.15 75.66 73.11 74.23 INR 731 1,006 732 674 592 Fx Loan restated in 4,766.9 6,959.0 5,549.2 4.928.8 4,391.3 INR 103 248 Rupee Loan 4.1 8.1 16.9 43.6 (0.1) 57 180 110 102 10 23 18 33 Gross De
Slide 13: Filing Status
} | AUROBIND Committed to healthier life! 203 Windsor Center Drive
Slide 14: US Filings Snapshot as on 30th September 2021
US Filings Snapshot as on 30th September 2021 ANDA Filings Addressable 456 Therapy ANDAs Market Size 355 (US$ Bn) Non - Injectables 101 Injectables 196 CNS 118 24.0 171 54 CVS 99 27.7 29 ARV** 39 4.8 Final Tentative Under Gastroenterological 36 3.4 Approved Awaiting final Approval Approval Review Ap
Slide 15: Global regulatory filing details
Global regulatory filing details As at As at As at As at As at As at As at As at Sep Category Approvals Mar 15 Mar 16 Mar 17 Mar 18 Mar 19 Mar 20 Mar 21 21 Formulations US* 376 398 429 478 541 586 639 681 485 (FA: 456, TA:29) 2,820 Dossiers (333 Europe** 1,756 2,224 2,521 2,848 3,003 3,214 3,374 3,5
Slide 16: Thank You
Thank You For more information, contact Arvind Bothra Investor Relations | Corporate Communications +91 40 6672 5401 ir@aurobindo.com www.aurobindo.com